SG11201811745UA - T cell compositions for immunotherapy - Google Patents
T cell compositions for immunotherapyInfo
- Publication number
- SG11201811745UA SG11201811745UA SG11201811745UA SG11201811745UA SG11201811745UA SG 11201811745U A SG11201811745U A SG 11201811745UA SG 11201811745U A SG11201811745U A SG 11201811745UA SG 11201811745U A SG11201811745U A SG 11201811745UA SG 11201811745U A SG11201811745U A SG 11201811745UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- june
- pct
- immunotherapy
- cell compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 3
- 238000009169 immunotherapy Methods 0.000 title abstract 3
- 108010002350 Interleukin-2 Proteins 0.000 abstract 5
- 108700012920 TNF Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000012099 Alexa Fluor family Substances 0.000 abstract 1
- 101710145634 Antigen 1 Proteins 0.000 abstract 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 abstract 1
- 101150106931 IFNG gene Proteins 0.000 abstract 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 abstract 1
- 102000003729 Neprilysin Human genes 0.000 abstract 1
- 108090000028 Neprilysin Proteins 0.000 abstract 1
- 241000656145 Thyrsites atun Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000004172 quinoline yellow Substances 0.000 abstract 1
- 230000009257 reactivity Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4201—Neoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111110111111111011111111 01111101011H011111110011111011101111111011110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2018/005712 Al 04 January 2018 (04.01.2018) W I PO I PCT (51) International Patent Classification: (74) Agent: SOMERVILLE, Deborah, A. et al.; Fox Roth- C12N 5/078 (2010.01) CO7K 14/54 (2006.01) schild LLP, Princeton Pike Corporate Center, 997 Lenox C12N 5/0783 (2010.01) CO7K 14/55 (2006.01) Drive, Bldg. 3, Lawrenceville, NJ 08648-2311 (US). C12N 5/0786 (2010.01) A61K 35/17 (2015.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/US2017/039846 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (22) International Filing Date: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 28 June 2017 (28.06.2017) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (25) Filing Language: English KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (26) Publication Language: English MG, MK, MN, WV, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (30) Priority Data: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 62/355,533 28 June 2016 (28.06.2016) US TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 62/355,506 28 June 2016 (28.06.2016) US (84) Designated States (unless otherwise indicated, for every 62/355,458 28 June 2016 (28.06.2016) US kind of regional protection available): ARIPO (BW, GH, (71) Applicant: GENEIUS BIOTECHNOLOGY, INC. GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, [US/US]; 12 Michigan Drive, Natick, MA 01760 (US). UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (72) Inventors: SLANETZ, Alfred, E.; 14 Nichols Road, Co- EE, ES, FL FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, hasset, MA 02025 (US). NAKAGAWA, Terry, Y.; 3359 — MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 5M, = Church Street, Evanston, IL 60203 (US). HERRMAN, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Marissa, A.; 1118 Saratoga Street, Apt. 2, Boston, MA KM, ML, MR, NE, 5N, TD, TG). 02128 (US). = (54) Title: T CELL COMPOSITIONS FOR IMMUNOTHERAPY = = = 10 5 cD 104 Pentamer+ 1.10 10 6 105 crs CD107a+ Gamma+ 2 22 -- :\"V 107a+ 0.46 10 6 10 5 03 TNFa 0 25 TNFa IL-2 0.059 E = Antigen 2 6 - 104 '' 104 = C D 103 _ ci_ — 0 = - 103 E (-) 10 0 3 -10 IFNg+ 1.82 1 — 0 .104 IL-2 0.14 0 10 2 10 3 10 4 10 5 = = Comp-BL1-H :: CD197-Alexa = Fluor 48 — 109-Control = CD8+ _ 127395 10 3 0 10 3 IFNy C5 109 fcs 10 4 10 5 -10 3 0 10 3 10 4 10 5 IL-2 C5 109 fcs 10 6 1111111111.11•1 10 6 = 1 0 Pentamer+ 10 5 CD10 7 a+ 62 CI Gamra+ 1 07 a+ 10 5 INF - NFa+ IL -2+ 21.1 E 104 +Antigen 1° m 4 1 -- 10 cz, v3 4 u- 1 o = 1- -. 11 a) 0 10 3 0- -10 3 c-) 0 103 -103 IFN g 10 4 0 -104 -+ IL2 3.5 ei 1-1 10 1 IN ir) Comp-BL1-H 0 --.... 00 1-1 0 (57) : The invention relates ei antigens that are useful for adoptive immunotherapy and methods for making the T cell compositions. C 10 2 10 3 10 4 10 5 :: CD197-Alexa Fluor 48 to compositions comprising -10 3 0 10 3 10 10 5 IFN 7 a heterogeneous population FIG. 6C -10 3 0 10 10 4 105 IL-2 of T cells with reactivity to selected [Continued on next page] WO 2018/005712 Al D ill Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event amendments (Rule 48.2(h)) of receipt of
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662355458P | 2016-06-28 | 2016-06-28 | |
| US201662355533P | 2016-06-28 | 2016-06-28 | |
| US201662355506P | 2016-06-28 | 2016-06-28 | |
| PCT/US2017/039846 WO2018005712A1 (en) | 2016-06-28 | 2017-06-28 | T cell compositions for immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811745UA true SG11201811745UA (en) | 2019-01-30 |
Family
ID=60787739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811745UA SG11201811745UA (en) | 2016-06-28 | 2017-06-28 | T cell compositions for immunotherapy |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20200237819A1 (en) |
| EP (1) | EP3487990A4 (en) |
| JP (3) | JP7034955B2 (en) |
| KR (1) | KR20190037243A (en) |
| CN (1) | CN109715788A (en) |
| AU (2) | AU2017290119A1 (en) |
| CA (1) | CA3068387A1 (en) |
| IL (1) | IL263896A (en) |
| MX (1) | MX2019000180A (en) |
| SG (1) | SG11201811745UA (en) |
| WO (1) | WO2018005712A1 (en) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011028531A1 (en) | 2009-08-24 | 2011-03-10 | Baylor College Of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| PT2812431T (en) | 2012-02-09 | 2019-10-18 | Baylor College Medicine | PEPMIXES TO GENERATE MULTIVIRAL CTLS WITH WIDE SPECIFICITY |
| IL294055A (en) * | 2015-03-20 | 2022-08-01 | Childrens Nat Medical Ct | Production of t-cells specific for a virus antigen or other antigen from a population of naïve t-cells |
| MX2019004707A (en) | 2016-10-26 | 2019-08-12 | Iovance Biotherapeutics Inc | RE-STIMULATION OF CRYOCONSERVED INFILTRATING TUMOR LYMPHOCYTES. |
| TWI788307B (en) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion |
| KR102618948B1 (en) | 2016-11-17 | 2023-12-27 | 이오반스 바이오테라퓨틱스, 인크. | Residual tumor infiltrating lymphocytes and methods of making and using the same |
| WO2018129336A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
| CN110199017A (en) | 2017-01-20 | 2019-09-03 | 国立大学法人京都大学 | CD8 alpha+beta+cytotoxic T cell preparation method |
| US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| JOP20190224A1 (en) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | Operations for the production of tumor-infiltrating lymphocytes and their use in immunotherapy |
| TW201930340A (en) * | 2017-12-18 | 2019-08-01 | 美商尼恩醫療公司 | Neoantigens and uses thereof |
| BR112020013848A2 (en) | 2018-01-08 | 2020-12-01 | Iovance Biotherapeutics, Inc. | methods for expanding tumor-infiltrating lymphocytes and for treating an individual with cancer, tumor-infiltrating lymphocyte population, and, method for evaluating transcription factors |
| WO2019217753A1 (en) | 2018-05-10 | 2019-11-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| JP7198602B2 (en) * | 2018-07-11 | 2023-01-04 | カワサキモータース株式会社 | motorcycle |
| JPWO2020027094A1 (en) * | 2018-07-31 | 2021-09-16 | サイアス株式会社 | A method for producing a regenerated T cell population via iPS cells |
| WO2020025706A1 (en) * | 2018-07-31 | 2020-02-06 | Polybiocept Gmbh | Production and selection of tumor uber reactive immune cells (turics) |
| JP7495137B2 (en) * | 2018-08-10 | 2024-06-04 | ユーティレックス カンパニー リミテッド | Cancer antigen-specific cytotoxic T cells |
| CN113302285A (en) * | 2018-08-10 | 2021-08-24 | 优特力克斯有限公司 | Preparation and cryopreservation method of cancer antigen specific CD8+ T cells |
| EP3872087B1 (en) * | 2018-10-26 | 2024-09-25 | Shinshu University | High-efficiency method for producing genetically modified cells |
| EP3873540A4 (en) | 2018-10-31 | 2022-07-27 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF CANCER |
| EP3873500A4 (en) | 2018-10-31 | 2023-01-11 | Mayo Foundation for Medical Education and Research | CANCER TREATMENT METHODS AND MATERIALS |
| JOP20210094A1 (en) | 2018-11-05 | 2023-01-30 | Iovance Biotherapeutics Inc | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| WO2020102701A1 (en) * | 2018-11-16 | 2020-05-22 | Rapa Therapeutics, Llc | Methods for the manufacture of th1/tc1 phenotype t cells |
| MX2021007353A (en) * | 2018-12-18 | 2021-11-17 | Beth Israel Deaconess Medical Ct Inc | GENERATION OF ORGANOID SENSITIZED T CELLS (OPT) WITH MEMORY PHENOTYPE. |
| US20220064598A1 (en) * | 2019-01-07 | 2022-03-03 | Children's National Medical Center | Ex vivo activated t-lymphocytic compositions and methods of using the same |
| JP7649244B2 (en) * | 2019-02-14 | 2025-03-19 | リサーチ インスティテュート アット ネイションワイド チルドレンズ ホスピタル | Use of stimulating agents to assay the potency of immune cells |
| BR112021019669A2 (en) | 2019-04-12 | 2021-12-07 | C4 Therapeutics Inc | Compound, pharmaceutical composition, method of treating a disorder, compound for use in the production of a medicine, and, use of a compound in treating a disorder |
| EP3976068A4 (en) * | 2019-05-31 | 2023-08-09 | Children's National Medical Center | CYTOKIN COCKTAILS FOR SELECTIVE EXPANSION OF T-CELL SUBSETS |
| JP7337373B2 (en) * | 2019-07-29 | 2023-09-04 | サイアス株式会社 | Method for producing antigen-specific T cells |
| CN114615886A (en) * | 2019-08-29 | 2022-06-10 | 得克萨斯大学体系董事会 | Cell cryopreservation culture medium |
| CA3162703A1 (en) * | 2019-11-27 | 2021-06-03 | Myst Therapeutics, Llc | Method of producing tumor-reactive t cell composition using modulatory agents |
| US20230028788A1 (en) * | 2019-12-23 | 2023-01-26 | Baylor College Of Medicine | T cell performance assay as a prognostic factor for clinical outcome |
| US12378521B2 (en) | 2020-04-15 | 2025-08-05 | Amgen Inc. | Method for enhancing production of genetically engineered autologous T cells |
| US12241086B2 (en) | 2020-04-15 | 2025-03-04 | Amgen Inc. | Process for generating genetically engineered autologous T cells |
| AU2021388167A1 (en) * | 2020-11-25 | 2023-07-06 | Geneius Biotechnology, Inc. | Antigen specific t cells and methods of making and using same |
| CN113481157B (en) * | 2021-07-21 | 2023-03-17 | 上海赛傲生物技术有限公司 | Optimized preparation method of specific antiviral adoptive immune cells |
| CN113564116B (en) * | 2021-07-21 | 2023-08-01 | 北京赛傲生物技术有限公司 | Preparation method of specific antiviral adoptive immune cell CE |
| CN113512529B (en) * | 2021-07-21 | 2022-11-25 | 上海赛傲生物技术有限公司 | Preparation method of specific antiviral adoptive immune cell AB |
| KR20240052771A (en) * | 2021-09-08 | 2024-04-23 | 케이에스큐 세러퓨틱스 인코포레이티드 | Lymphocyte potency assay |
| US20250325668A1 (en) * | 2021-10-08 | 2025-10-23 | Baylor College Of Medicine | Targeting common somatic mutations in breast cancer with neo-antigen specific adoptive t cell therapy |
| JP2023064787A (en) * | 2021-10-27 | 2023-05-12 | 国立大学法人京都大学 | Quality evaluation method of t-cell, and reagent used in the method |
| US20250223552A1 (en) * | 2022-03-18 | 2025-07-10 | St. Jude Children's Research Hospital, Inc. | Method for preparing t cells for adoptive t cell therapy |
| EP4507704A1 (en) | 2022-04-15 | 2025-02-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1078263T3 (en) * | 1998-05-11 | 2009-11-02 | Miltenyi Biotec Gmbh | Method for direct selection of antigen-specific T cells |
| AU2003258090B2 (en) * | 2002-08-08 | 2010-07-22 | Baylor College Of Medicine | Isolation and identification of T cells |
| HUE024541T2 (en) * | 2008-05-14 | 2016-01-28 | Immatics Biotechnologies Gmbh | Novel and powerful MHC-class II peptides derived from survivin and neurocan |
| WO2011028531A1 (en) * | 2009-08-24 | 2011-03-10 | Baylor College Of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| US9114100B2 (en) * | 2010-05-17 | 2015-08-25 | Duke University | Methods of treatment using ex vivo expansion of cord blood T cells |
| CA2874431A1 (en) * | 2011-05-26 | 2012-11-29 | Geneius Biotechnology Investments, Llc | Method for making t cell population directed to subdominant antigens or epitopes |
| US10316289B2 (en) | 2012-09-06 | 2019-06-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T memory stem cell populations |
| CN106687584B (en) * | 2014-09-04 | 2021-08-13 | 干细胞技术公司 | Soluble antibody complexes for T cell or NK cell activation and expansion |
| US10993997B2 (en) * | 2014-12-19 | 2021-05-04 | The Broad Institute, Inc. | Methods for profiling the t cell repertoire |
| MA42895A (en) * | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | MODIFIED CELLS FOR ADOPTIVE CELL THERAPY |
-
2017
- 2017-06-28 EP EP17821200.7A patent/EP3487990A4/en active Pending
- 2017-06-28 US US16/312,023 patent/US20200237819A1/en not_active Abandoned
- 2017-06-28 CA CA3068387A patent/CA3068387A1/en active Pending
- 2017-06-28 JP JP2018569009A patent/JP7034955B2/en active Active
- 2017-06-28 MX MX2019000180A patent/MX2019000180A/en unknown
- 2017-06-28 WO PCT/US2017/039846 patent/WO2018005712A1/en not_active Ceased
- 2017-06-28 AU AU2017290119A patent/AU2017290119A1/en not_active Abandoned
- 2017-06-28 SG SG11201811745UA patent/SG11201811745UA/en unknown
- 2017-06-28 KR KR1020197002828A patent/KR20190037243A/en not_active Ceased
- 2017-06-28 CN CN201780053540.8A patent/CN109715788A/en active Pending
-
2018
- 2018-12-23 IL IL263896A patent/IL263896A/en unknown
-
2022
- 2022-03-02 JP JP2022031731A patent/JP2022066355A/en active Pending
- 2022-06-16 US US17/807,213 patent/US20230145991A1/en active Pending
-
2023
- 2023-10-26 AU AU2023254998A patent/AU2023254998A1/en active Pending
-
2024
- 2024-05-22 JP JP2024083379A patent/JP2024103547A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN109715788A (en) | 2019-05-03 |
| US20200237819A1 (en) | 2020-07-30 |
| JP2019519246A (en) | 2019-07-11 |
| MX2019000180A (en) | 2019-11-05 |
| IL263896A (en) | 2019-01-31 |
| CA3068387A1 (en) | 2018-01-04 |
| AU2023254998A1 (en) | 2023-11-16 |
| KR20190037243A (en) | 2019-04-05 |
| WO2018005712A1 (en) | 2018-01-04 |
| JP2024103547A (en) | 2024-08-01 |
| JP2022066355A (en) | 2022-04-28 |
| JP7034955B2 (en) | 2022-03-14 |
| US20230145991A1 (en) | 2023-05-11 |
| EP3487990A4 (en) | 2020-07-29 |
| AU2017290119A1 (en) | 2019-01-24 |
| EP3487990A1 (en) | 2019-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811745UA (en) | T cell compositions for immunotherapy | |
| SG11201809710RA (en) | Genetically engineered cells and methods of making the same | |
| SG11201806951TA (en) | Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers | |
| SG11201806758VA (en) | Vcn enhancer compositions and methods of using the same | |
| SG11201803701YA (en) | Methods and compositions for gene editing in hematopoietic stem cells | |
| SG11201908527SA (en) | High affinity mage-a1-specific tcrs and uses thereof | |
| SG11201805449PA (en) | Methods of making chimeric antigen receptor -expressing cells | |
| SG11201807300PA (en) | Uterine cancer treatments | |
| SG11201808797XA (en) | T cell receptors | |
| SG11201908337VA (en) | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells | |
| SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
| SG11201909652WA (en) | Neoantigen identification, manufacture, and use | |
| SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
| SG11201806577UA (en) | Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers | |
| SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
| SG11201806400XA (en) | Replicative transposon system | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201808629UA (en) | Immunotherapy against melanoma and other cancers | |
| SG11201408787PA (en) | Enhancing activity of car t cells by co-introducing a bispecific antibody | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201907508WA (en) | Single slot short pucch with support for intra slot frequency hopping | |
| SG11201901176XA (en) | Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers | |
| SG11201810591VA (en) | Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen | |
| SG11201407818PA (en) | High-capacity storage of digital information in dna | |
| SG11201908675PA (en) | Computer-implemented system and method for performing transaction mixing on a blockchain |